Telangana has 200+ FDA-approved pharma sites: Rama Rao, KT.
As the Minister put it, "Hyderabad Pharma City will be the largest and most sustainable integrated pharma park in the world," Its launch will further strengthen the State's capabilities.
Industries Minister KT Rama Rao stated that Telangana was the only region in the world to have over 200 FDA-approved sites for pharmaceutical manufacturing, which produced both innovator and generic medicines and accounted for 40% of India's Pharma production.
At the opening ceremony of BioAsia 2023, he said that the launch of Hyderabad Pharma City, the largest and most environmentally friendly integrated pharma park in the world, would significantly boost the State's capacity.
Several companies have already stated their intention to locate operations in the Pharma City, which can potentially bring in $8 billion in investments.
Hyderabad's key players like Dr. Reddy's Laboratories, Biological E, Bharat Biotech, Shantha Biotech, Aurobindo, Hetero, Gland Pharma, and Virchow Biotech have made the city the country's leader in biological production. In addition, Telangana is building India's first Growth-Phase Center and Biopharma Scale-up Manufacturing facility, called Biopharma the Hub (B-hub).
There were also plans to invest in the emerging cell and gene therapy field. An Institute of Curative Medicine was planned to open in Hyderabad to make developing and commercializing these therapies more accessible and affordable for diseases affecting India's population.
It became clear that Hyderabad quickly became the go-to spot for life sciences-focused Global capability centers (GCCs). In addition to Novartis, Bayer, Medtronic, Thermofisher, and Schrodinger, BMS and Sanofi have announced the construction of new facilities in Hyderabad. These GCCs will support the worldwide R&D, analytics, innovation, and engineering communities within the next five years. He went on to say that the state plans to promote Hyderabad as a premier location in the GCC for the industry's most prestigious life sciences corporations.
Comments